Insider Purchases: Inside the Buy
Tag: CFO Insider Buying
Eastman Chemical (EMN): Insider Chemistry at Work
Insiders from CEO to CFO are scooping up Eastman Chemical shares. With institutions owning 92% of the float and dividends flowing, is this a value play worth a reaction? 🧪📈
Amrize Will Rise, Insiders Undoubtedly Think
Amrize insiders are loading up on stock like it’s on sale at Home Depot. With infrastructure and housing tailwinds, it’s tempting — but watch out for valuation cracks.
MaxCyte (MXCT) — Insiders Load Up While Cash Burns
MaxCyte insiders are shopping biotech shares like it’s Black Friday 🛒💉. With revenue slipping, cash burning, but institutions holding, is MXCT a comeback spark ⚡ or a treadmill burn-out 🔥?
Financials Paint a Dire Story… But Tronox’s CEO and Insiders See Light in the TiO₂ Pigment
Tronox isn’t just about titanium dioxide anymore—it’s about insider confidence, global reach, and whether this chemical giant’s bright white future is worth your green 💵. From insider purchases to institutional moves, here’s why investors might want to watch TROX closely.
New CEO Buys In at Dave & Buster’s ($PLAY). Who Doesn’t Like a Little PLAY in Their Portfolio — or Life?
New CEO Tarun Lal takes the reins—and a big slice of $PLAY stock. With insiders buying, institutions overloaded, and sales trends improving, could this be the next comeback classic of the “entertainment” era?
Simmons Bank: Insider Buys, 116 Years of Dividends, and a Footlong Public Offering
Simmons Bank has paid dividends for over a century—and insiders just went on a buying spree. 📉 Stock’s dipped, 🔍 valuation isn’t screaming cheap, but with improving net income and institutional support, SFNC might be worth a second look. If not exciting, at least it’s… dependable?
Helen of Troy (HELE) — Insider Buys, CFOs Turned CEOs, and a Falling Knife You Might Want to Catch (Carefully)
The CEO and CFO of Helen of Troy just bought shares as the stock plunges 90%. Are we looking at a tragic tale, or a comeback for the ages? We dig into the numbers, leadership shuffle, and Wall Street signals—with humor and historical flair.
Xerox Holdings: This Company Still Exists—To Be or Not To Be... In Your Portfolio?
Xerox might feel like yesterday’s news, but insiders and institutions clearly disagree. With executives loading up on shares and a reinvention strategy underway, this classic name could be more than a relic—it might just be your next contrarian play. 📠💥
Ligand Pharmaceuticals (LGND): In a League of Its Own? Insiders Think So!
Ligand Pharma (LGND) isn’t chasing moonshots—it’s collecting royalties across a sprawling biotech empire. With both the CEO and CFO buying in, and a royalty engine showing 46% revenue growth, insiders may know something. Is this the most compelling quiet biotech turnaround on the Nasdaq?
🔬 Illumina (ILMN): Let’s Illuminate the Bull Case!
After losing nearly 80% of its value since 2021, Illumina (ILMN) may be ready for a glow-up. CEO Jacob Thaysen and CFO Ankur Dhingra just bought big, and institutional holders are still hanging on. What do they see—and should you see it too?